Cargando…
A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MA...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282775/ https://www.ncbi.nlm.nih.gov/pubmed/37350940 http://dx.doi.org/10.3389/fonc.2023.1143401 |
_version_ | 1785061193126248448 |
---|---|
author | He, Li-li Xiao, Shuai Jiang, Cui-hong Wu, Xiang-wei Liu, Wen Fan, Chang-gen Ye, Xu Zhao, Qi Wu, Wen-qiong Li, Yan-xian Wang, Hui Liu, Feng |
author_facet | He, Li-li Xiao, Shuai Jiang, Cui-hong Wu, Xiang-wei Liu, Wen Fan, Chang-gen Ye, Xu Zhao, Qi Wu, Wen-qiong Li, Yan-xian Wang, Hui Liu, Feng |
author_sort | He, Li-li |
collection | PubMed |
description | PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: Between July 15, 2020, and January 31, 2022, a randomized controlled phase II trial was conducted. Eligible patients (N=282, 18-70 years old) with pathologically diagnosed LA-NPC were randomly assigned to receive CBT or treatment as usual (TAU) during CCRT (computer-block randomization, 1:1). The primary endpoints were the incidence and latency of oral mucositis. RESULTS: The incidence of oral mucositis was significantly lower in the CBT group (84.8%; 95% confidence interval [CI], 78.7%-90.9%) than in the TAU group (98.6%; 95% CI, 96.6%-100%; P<0.001). The median latency period was 26 days and 15 days in the CBT and TAU groups, respectively (hazard ratio, 0.16; 95% CI, 0.12-0.22; P<0.001). CBT significantly reduced ≥ grade 3 oral mucositis (71.9% vs. 22.5%, P<0.001), dry mouth (10.8% vs. 3.7%, P=0.021), dysphagia (18% vs. 5.1%, P=0.001), and oral pain (10% vs. 3.6%, P=0.034) compared with TAU. Patients receiving CBT and TAU during CCRT had similar short-term response rates. CONCLUSIONS: CBT reduced the occurrence, latency, and severity of oral mucositis in patients with LA-NPC during CCRT. |
format | Online Article Text |
id | pubmed-10282775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102827752023-06-22 A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy He, Li-li Xiao, Shuai Jiang, Cui-hong Wu, Xiang-wei Liu, Wen Fan, Chang-gen Ye, Xu Zhao, Qi Wu, Wen-qiong Li, Yan-xian Wang, Hui Liu, Feng Front Oncol Oncology PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: Between July 15, 2020, and January 31, 2022, a randomized controlled phase II trial was conducted. Eligible patients (N=282, 18-70 years old) with pathologically diagnosed LA-NPC were randomly assigned to receive CBT or treatment as usual (TAU) during CCRT (computer-block randomization, 1:1). The primary endpoints were the incidence and latency of oral mucositis. RESULTS: The incidence of oral mucositis was significantly lower in the CBT group (84.8%; 95% confidence interval [CI], 78.7%-90.9%) than in the TAU group (98.6%; 95% CI, 96.6%-100%; P<0.001). The median latency period was 26 days and 15 days in the CBT and TAU groups, respectively (hazard ratio, 0.16; 95% CI, 0.12-0.22; P<0.001). CBT significantly reduced ≥ grade 3 oral mucositis (71.9% vs. 22.5%, P<0.001), dry mouth (10.8% vs. 3.7%, P=0.021), dysphagia (18% vs. 5.1%, P=0.001), and oral pain (10% vs. 3.6%, P=0.034) compared with TAU. Patients receiving CBT and TAU during CCRT had similar short-term response rates. CONCLUSIONS: CBT reduced the occurrence, latency, and severity of oral mucositis in patients with LA-NPC during CCRT. Frontiers Media S.A. 2023-06-07 /pmc/articles/PMC10282775/ /pubmed/37350940 http://dx.doi.org/10.3389/fonc.2023.1143401 Text en Copyright © 2023 He, Xiao, Jiang, Wu, Liu, Fan, Ye, Zhao, Wu, Li, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology He, Li-li Xiao, Shuai Jiang, Cui-hong Wu, Xiang-wei Liu, Wen Fan, Chang-gen Ye, Xu Zhao, Qi Wu, Wen-qiong Li, Yan-xian Wang, Hui Liu, Feng A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title | A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title_full | A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title_fullStr | A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title_full_unstemmed | A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title_short | A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
title_sort | randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282775/ https://www.ncbi.nlm.nih.gov/pubmed/37350940 http://dx.doi.org/10.3389/fonc.2023.1143401 |
work_keys_str_mv | AT helili arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT xiaoshuai arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT jiangcuihong arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wuxiangwei arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liuwen arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT fanchanggen arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT yexu arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT zhaoqi arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wuwenqiong arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liyanxian arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wanghui arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liufeng arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT helili randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT xiaoshuai randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT jiangcuihong randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wuxiangwei randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liuwen randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT fanchanggen randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT yexu randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT zhaoqi randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wuwenqiong randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liyanxian randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT wanghui randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy AT liufeng randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy |